✦ LIBER ✦

P.3.076 Bifeprunox: a novel atypical antipsychotic with in vivo 5-HT1A receptor agonistic activity

Book ID: 118591994
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 119 KB
Volume: 15
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(05)81012-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.3.074 Bifeprunox: a novel atypical ant

P.3.074 Bifeprunox: a novel atypical antipsychotic sharing dopamine D(2,3,4) receptor and serotonin 5-HT(1A) receptor affinities

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 123 KB

In vivo evidence of central 5-HT1A agoni

In vivo evidence of central 5-HT1A agonist activity of the novel antipsychotic ziprasidone

✍ H. Rollema; J.S. Sprouse; Y. Lu; L.S. Reynolds; J.P. Braselton; S.H. Zom 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Novel antipsychotic agents with 5-HT1A a

Novel antipsychotic agents with 5-HT1A agonist properties: Role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats

✍ Mark S. Kleven; Catherine Barret-Grévoz; Liesbeth Bruins Slot; Adrian Newman-Tan 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 229 KB

Preferential in vivo action of F15599, a

Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors

✍ L Lladó-Pelfort; M-B Assié; A Newman-Tancredi; F Artigas; P Celada 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 893 KB

Effects of novel 5-HT1A receptor antagon

Effects of novel 5-HT1A receptor antagonists on measures of postsynaptic 5-HT1A receptor activation in vivo

✍ Richard J. Thielen; Alan Frazer 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 470 KB

Treatment of cognitive dysfunction in ch

Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist

✍ Danijela Piškulić; James S. Olver; Paul Maruff; Trevor R. Norman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract ## Objectives To assess effects of a semi‐acute administration of buspirone in comparison to a placebo on cognitive function and negative symptoms in patients with schizophrenia and schizoaffective disorder. ## Methods In a 6‐week, double‐blind, placebo‐controlled, independent groups